Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.53 by 3.27 percent. This is a 15.51 percent decrease over earnings of $1.87 per share from the same period last year.
HTG Molecular Diagnostics Granted Australian Patent Titled ‘METHODS FOR SUBTYPING DIFFUSE LARGE B-CELL LYMPHOMA’
http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2016331058#